APCONIX
a better decision

drug safety FORUM

Making Safety
Part of Drug Design

Magdalene College, Cambridge
October 12th 2023
9am - 5pm

Time	Title	Speaker
9-945	**Arrival and Registration - Coffee and Pastries**	
945-10	Introduction	Professor Ruth Roberts, ApconiX
Opening Keynote		
10-1030	Reducing the Risk of Mitochondrially Active Compounds in Medicines Development	Dr Jon Lyon, Director of Preclinical Toxicity and Mitochondrial Network Lead, GSK
Morning Session		
1030-11	Assessing Cardiac Ion Channel Activity in the Drug Discovery Cascade	Dr Mike Morton, ApconiX
11-1130	Making formulation part of drug design: case studies	Dr Linette Ruston, Director, ADME and Modelling Sciences, SEDA Pharmaceuticals
1130-12	The role of Target Safety Assessments (TSAs) in de-risking drug projects	Dr James Sidaway, ApconiX
12-13	**Lunch Break**	
Afternoon Session		
13-1330	Interfacing DMPK and Safety in Drug Design: Concentration effect relationships	Dr Kevin Beaumont, Senior Director, DMPK, AstraZeneca
1330-14	Developing an ion channel seizure panel	Dr Kim Rockley, ApconiX
14-1430	Designing out secondary pharmacology hits	Dr Mark Anderton, Senior Principal Scientist, MSD
1430-15	**Coffee/Tea**	
15-1530	State-of-the-art cellular models in de-risking drug design	Dr Colin Brown, Chief Innovation Officer, Newcells Biotech
1530-1600	Making safety part of drug design – a regulatory perspective	Dr David Jones, ApconiX
1600	Panel discussion	Dr David Jones Dr Richard Knight Dr Anthony Holmes Dr Muireann Coen
1630	**Close**	

subject to change.